Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For the moment, MORNINGSTAR evaluation reads:
1- UNDERVALUED
2- Fair value at $0,59 cents (current pps at + or - $0.23)
Whatever that means ???
I like that ...
THE VERY GOOD FOOD COMPANY ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES - 09/08/2022 8:30:00 AM
VANCOUVER, BC, Sept. 8, 2022 /PRNewswire/ - The Very Good Food Company Inc. (NASDAQ: VGFC) (TSXV: VERY.V) (FSE: OSI) ("VERY GOOD" or the "Company"), a leading plant-based food technology company, today announced that it has initiated a process to evaluate potential strategic alternatives to maximize shareholder value, which could include the acquisition by, or a merger with, an industry partner involving all or part of VERY GOOD's business or assets.
The Very Good Food Company Inc. Logo (CNW Group/The Very Good Food Company Inc.)
While the strategic review process is ongoing, the Company will remain focused on the successful implementation of its three-prong approach to (1) Stabilize, (2) Right-Size, and (3) Optimize, first announced in May 2022, to maintain and enhance the value of VERY GOOD's business and operations.
There can be no assurance that the strategic review process will result in any strategic alternative, or any assurance as to its outcome or timing. VERY GOOD has not set a timetable for completion of the review process and does not intend to disclose developments related to the process unless and until it executes a definitive agreement with respect thereto, or it otherwise determines that further disclosure is appropriate or required.
VERY GOOD has retained Canaccord Genuity Corp. as its financial advisor for the review of strategic alternatives.
I assume Leon has a plan but heck he should show it up somewhat instead of just reorganizing the debts.
Patience I intend to have. However I think we lose a lot of time, opportunities and revenues by only placing boxes on shelves not telling target consumers what we offer and what the product looks like so mothers can give it attention when they go by our shelves.
How often do people buy products they know nothing about?
I believe in this investment (my largest up to now) but cannot understand the stubborness of our CEO relative to talking to our potential customers. All she seems to understand is R&D and mandatory information releases to shareholders.
Frustrated but believe she may endup figuring out what has to be done .... before it's to late (competitors will not wait doing nothing.
'' ... notes now in default and the crazy June note with the $150K penalty, variable rate interest, 24% default penalty ... Leonite solidified its claim with the $745K June note due in 6 months. In addition there is $700K in convertible preferred shares of Cranberry Cove which holds the Canadian property, $400K in Ethema (GRST) series "B" preferred shares which is senior to all others, and other senior secured debt. ... The other stake holders need to catch up and make their claims as well because this appears to finally be unraveling ... The original $3.2 million in series "N" notes is now $3.9 million. It would appear that the interest has been rolled over into the notes ...
My hypothetical scenario would resolve all debts and shareholders (in particular the one (s) 'dumping in' millions would then hold 120,000,000 shares in a company having 200,000,000 O/S and 800,000,000 A/S left over.
That company would be debt (and notes) free, have cash on hand and an annual revenue of more than $5,000,000 right on day one.
So what do you think:
1- this company would be worth? (market cap)
2- What multiplier woud be appropriate
' ... to dump $10 million to bail this out with no expectation of a return ...''
1- $10,000,000 was an example
@ as for return: Can you tell me how much a company with no debt, cash on hand and an established revenue of $5,000,000 (based on last quarter ended 3 months ago ) could be worth in the market (market cap)?
Quote: 'They seem to just be running out the clock at this point and kicking the can down the road a bit more'.
Question: How do you justify that Leon would be only doing that? Why not just shut the door once and for all? Why are the lenders still play with him notwithstanding the story you so much enjoy painting?
Question? Could it be that all these people do believe in the future of that venture?
For sure it's speculation but ...
... if we go only with speculating that future is just a straight projection of what was the past (as someone enjoys saying) then one as to conclude that Leon is not only incompetent but outright stupid.
All I did is SPECULATE, creating a logical scenario but my point was that: looking at the past and the current state of the business to project disaster is speculation also.
I could also speculate that government programs could become available or whatever else I could imagine. I however did try to put up a theoritical scenarion making sense (unless proven wrong)
By the way, why does Leon keep working at putting back this boat afloat???
Quote: 'Scenarios with inflated revenue numbers with very little in net operating earnings aren't going to work.' ...
Question: I tought you said debt was the critical factor. Now paying it changes nothing ??? If company cleans the debt it should then be able to both clean the debt and finance expansion ... ???
Quote: 'They are borrowing each quarter to cover and those willing to lend is running short. Two notes taken out in Q2 also matured in Q2 and went unpaid. Borrowed $240K against future earnings in Q2. The bulk of the $247K of cash generated from operations for the first 6 months of the year came from the Canadian property lease. That source of earnings is now in jeopardy with the mortgage maturing in July and not yet refinanced. Bottom line is that cash flow will not be able to repay the June Leonite note and default means that the company will become Leonite's personal ATM machine.'
Question: wouldn't this 'problem be resolved by a $10,000,000 cash arrival?
Quote:'I see little reason for an angle investor to swoop in and throw good money after bad.'
Question: Could it be that 'throwing good money in' would become a good invesdtment if the money throwned in was rendering the company a financially healthy venture?
Cost of the 6,000,000,000 shares acquired: $ 0'00167
O/S 10,000,000,000
Even only condidering $5,000,000 revenues already secured, all that would be needed for this investment to BREACK EVEN UP FRONT is to assume a multiple of 3,33 so the market cap becomes $16,700,000 (pps of 0,0167 pre R/S suggested).
This is hypothetical but bottom line, WHATEVER THE PAST SAYS AND YOU ENJOY REHASHING, their is a way out of the historic mess ... looking forward.
That's one small step for babies; one ... (missing the follow thru)
'it is nice to be on some shelves somewhere .... but ... what are they doing to get the product from shelves into baskets to the houses and into little boys and girls bellies?'
Thanks for saying it. Unfortunately our CEO thinks mothers will find it by themselves and suddenly figure out by themselves also what that new box on the shelve is all about.
'This distribution will help introduce Else to new health-conscious consumers'
I'm not going to repeat it (it seems to antagonize some) but this quote demonstrates once again she doesn't have a clue about what marketing is.
You are so good at analyzing the past and focussing on debts, let's se what you think about the following scenario?
1- Leon or someone else does acquire the remaining 6,000,000,000 A/S for $10,000,000 cash with the unique intent to clean out $10,000,000 of debts.
2- Leon thereafter would do a 1 for 50 shares R/S resulting into a 200,000,000 O/S.
Considering an annual revenue's expectation of $8,000,000 what then could a realistic market cap become instantly? Wouldn't then a multiple of 5 be quite conservative? After all GRST would be in a pretty financially good shape with new means to grow in a highly profitable industry.
If so, the market cap would become $40,000,000 and on the basis of 200,000,000 new O/S that would mean a pps of $0,20/sh.
By the way the 'Leon or the someone else' move would make him owner of 120,000,000 new shares worth $0,20 each. That would be $24,000,000 worth of shares .... Not bad return of 240% for a $10,000,000 investment.
Did our management give up on the cannabis business? Would be nice to inform shareholders if management has any respect for them.
''Isracann Biosciences Inc. is please to announce that it has signed a distribution agreement for Praesidio Health products with Pure Integrative Pharmacy'' (09/01/2022)
Anyone can refer me to what financial programs the governments do have to support the more than 15,000+ private treatment facilities specialized in drug treatment facilities providing counseling, behavioral therapy, medication, case management, and other types of services to persons with substance use disorders.
The estimated cost for substance misuse to society is more than $820 billion each year and is expected to continue increasing. Approximately $170 billion is in direct medical costs and more than $156 billion in lost productivity.
For God knows why, someone wants to keep the pps as low as possible. This situation makes no sense and I shall wait for the future of events. One fact is for sure, there is a business behind the stock, our leader is an experienced successful business person and continuous progress has been made during the last 12 months but is not reflected in our market cap.
The only complaining I do is relative to the CEO's lack of competence relative to promotion of our products. She may be (most likely) a great scientific person but if one look at the success she generated r5evenue wise, it's a shame.
But it is not ... It's a song I like a lot (LOL)
You obviously want to change the meaning of my post and that's your right.
Let's summarize:
For a full year, our CEO communicates (NR's) with shareholders covering her strategy (very much worth mentionning) of adding shelves on with to put products. She however make no effort to reach mothers who are our potential buyers.
Looking one year back, hat approach to marketing has been proven totally ineffective, our revenues still being outright inferior from what they should be.
Shareholders obviously think so since our PPS went down from CDN$ 2,85 to $0,85. If I may so the Else Nutrition stock has proven that the company is not doing what is required and leaves an opportunity go by.
Find the error.
On 2021-09-02,
- the stock traded at between ,0017 and ,0021 (volume was 24,000,00).
- Outstanding shares were: 2,900,000,000 for a
- market cap of between $5 and $6 millions.
- No revenues had ever been filed.
Today (noon on 2022-09-01)
- the stock trades at ,0005 and ,0006 (no volume),
- Outstanding shares are at (more or less) 3,800,000,000 for a
- market cap of between $2 and $2,3 millions.
- Revenues reported for Q2/2022 were $1,138,000.
Expectation is thar revenues for next year shall be $8M +++
This stock is manipulated to an extreme limit. Granted there are a lot of debts but on yhe otherhand, it generates $5 or $8 a year and its market cap is more or less 50% of that. By the way, one year ago we had more debts and no revenues worth mentionning.
The company operates a real business, files financials regulatly and its CEO is a serious entrepreneur stating up an operation.
Something is going on behind the scene ???
I must agree. Somehow management walked away from the cannabis business without informing us and now a new management starts a totally different business as if nothing did happen.
That is the risk one takes when playing on the crazy OTC pink market (like it is playing roulette)
Stuck with 100,000 shares ... just in case.
Once again the market said that adding shelves without informing the consumers is not going to do it. Obviously our CEO (and whoever is supposed to handle marketing) cannot care less about our market cap and revenues (I did not even mention profit).
All she cares about is R&D and getting shelves where products can be stored (I did not say can be sold). Whenever she needs cash, she prints new shares and there we go ...
Having been in marketing all my life (including with companies such as IBM) I cannot understand why our CEO is so stubborn relative to addressing the mothers we can serv now and setting up those we hope to serv in the future.
Finally having a real busines generating revenues Leon shall sooner than later make a win-win offer to his lenders who may not be able to refuse it anymore. I a poker, going all in is something generally done by the one having the least to lose.
The lenders up to now kept negociating better position with someone having not much to offer as a counterpart.
Now he has (almost) a solid business offering great growyh potential.
Unfortunately, lenders selfisly believes Leon to not have the guts to fold or go bancrupt id lenders do not play HIS game. Up to now Leon was on his knees but not anymore.
I suspect sooner than later Leon will make them an offer they cannot refuse. The offer (trade debt for up to 6,000,000,000 shares), at a pps representing the market value of current business,i writing offf the by trading it for shares.
Debt set aside, current market cap, (assuming as conservative a multiplier as 8) is $40,000,000+ (16 times current value or pps of 0,004 as a starting point).
Right after that, Leon make a 1 for 100 R/S, making the O/S 1,000,000,000 at $0,40.
The company now has no debt, a solid business and have means to finance its growth for the profit of all working together.
If such a reasonnable was to be refused, leon could tell lender that, being cornered by lenders trying to kill his business, he may as well fold now, declare bancrupcy and let the lenders writeoff most of the bookvalue of their loans.
Leon not being stupid and lenders being irresponsible, I suspect a showdown is close. ... We shall see.
After I described in details a possible win-win scenario (post removed) I wrote: 'The suggested scenario may not be what the parties are looking at but they must try (TOGETHER) to figure out a way to solve the current anomaly in a way making everyone a winner.'
Leonite as other lenders will have to figure out a way to solve the current mess with Leon, before Leon decides to pull the plug or worst. The debt now makes the market value = to more or less 50% of yearly revenues. That is the issue to be resolve and parties will have to do it sooner or later. Alternatively, Leon gives up, shut down the operation and declare bancrupcy and everyone is a looser.
For Leonite to keep getting notes and fees is great for their own books ... FOR NOW ... but that is if Leon keeps giving in to their blackmail. Calling their bluff is something that Leon could do and he would lose much less than the lenders.
Serious negociations must come because TAKING THE DEBT OUT OF THE BOOKS, GRST market value is worth (minimum) 10 times current annual revenues ($ 50,000,000) ... pps of 0125.
For the creditors (and Leon on a personal basis), instead of looking at this business as it usuall has been (looking backward is quite stupid) ... They could sit down and figure out a Win-Win (creditors and shareholders) scenario looking at projection of the CURRENT state of the business (instead of all the past history) as created against all odd by Leon.
Leon has effectively proven he could build a great business and creditors should notice that they can do great if they stop just doing 'more of the same' till they kill the gold egg chicken'.
Taking an upfront book loss (trading debt for shares worth half the value of the book value of their loans) in view of a rapid net book profit (seeing their shares increase by a factor of 2) based on a more than reasonnable growth of current market value of a financially healthy quasi startup company.
The suggested scenario may not be what the parties are looking at but they must try (TOGETHER) to figure out a way to solve the current anomaly in a way making everyone a winner. If they do not, they (and we) lose it all.
I personally believe that maximizing revenues (and profits) waiting for FDA's decision is THE way to minimize dilution if any and fund the groth.
I do not see what is wrong with this obviously sain strategy. Waiting till FDA does its thing before promoting our current offerings toward appropriate markets is (my opinion) ridiculous and makes no sense
After management accepted that their past strategy failed, they made drastic changes and, instead of just folding, created a new strategy aimed at saving the company starting with whatever they had to workk with. I expected to see the significant results of this new approach within 1 year or so from the time the decision was announced (mid 2023 or so).
By then, I expect pps to be what it was last March ($0,60 to $0,80) or better.
Looking forward to may be add to my position following isuing of current quarter's financials.
At $0,01 / shr our market cap would be less than 8 times our current annual revenues.
Leon obviously knows that his dept is the issue making the market value of the company only $2,5M or half is annual revenue going rate. I am pretty sure that he does spend a lot of time working at solving this problem and I wonder what plan he tries to execute to solve it ?
That's why I believe he keeps trying to work his way out of this mess when it would have been easier to just walk away from this mess months and moths ago.
That also explain why those seeing failure ahead, based on past irrelevant data, are totally wrong even trying to look smart.
I often said it: '
- GRST is a risky pinky offering great gain potential,
- GRST is traded on a dangerous market, manipulated by some,
- GRST has reduced debts and did grow revenues,
- GRST is managed by a successful executive who doesn’t try to BS people,
- GRST’S CEO is having significant initial success at reviving a company that was in a deep coma.
The company should have posted this message as a PR and have it showned every possible way.
As for explosive growth everything being relative, one has to notice that percentages are applied to very small numbers achieve without any effort to advertize.
This being said, notwithstanding our management business skills, the products they developped and the non-promoting-distribution efforts they did is the reason BABA is my most important investment. My impatience is caused by the fact that our growth (and base for future growth) is not what it could and should be.
Let's hope that following the FDA approval, this mentality of 'just waiting for things to happen' will change.
Opening my email box this morning
This email was sent to you because you signed up to receive Sergio Heiber Author Alerts.
Else Nutrition: Product Branding And Global Expansion Should Lead To Stock Price Appreciation
Aug. 25, 2022 9:20 AM ETElse Nutrition Holdings Inc. (BABY:CA), BABYF
Sergio Heiber
Summary
• Else will begin sales in Canada, China, and Europe.
• Sales have more than doubled online and expanded to over 3,000 retail outlets.
• Revenue is growing at an explosive pace.
• The company's future flagship product is progressing through the regulatory process.
Creativeye99/E+ via Getty Images
Else Nutrition Holdings (OTCQX: BABYF) [TSX: BABY] offers the world's only plant-based, non-dairy, non-soy nutrition. In previous articles, (1,2,3), I discussed why I have been bullish about this stock as there is a need for Else's products and I am impressed with how quickly the company is penetrating its addressable market. The stock price hasn't performed well since I initiated coverage, although Else has been making significant progress. The company experienced some delays in executing its plans due to the pandemic, similar to most other companies, but l estimate that the company will record a $10 million run rate this year and $25 million next year, compared to zero two years ago. These estimates assume no further delays from unforeseen events such as a pandemic or supply chain issues. In my view, this is a significant accomplishment. (All dollar figures in this article are in U.S. denomination)
Else is now expanding into being a global company developing a tremendous sales channel and establishing its brand with a portfolio of products. The progress made is enough to keep me feeling bullish about Else's future stock price. and there's a huge kicker as the company's future flagship product gets closer to clearing the regulatory process.
International expansion
The company just entered the Canadian market, commencing sales through Amazon.ca, and also added a partnership agreement with Gourmet Trading Co. for distribution to 5,000 Canadian brick-and-mortar locations.
Management has been working to establish sales in China for over a year. The kickoff date hasn't yet been disclosed. I suspect it will be within a month. There is already a distribution agreement with Bouzun, a leading Chinese online retailer. China not only offers the world's largest market but there's a huge opportunity there as almost all Chinese people suffer from lactose intolerance. From an article that appeared in Food Magazine:
Although there are no official figures, studies have indicated that lactose intolerance affects around 30% of Chinese children, and a study of Chinese adults showed that 92.3% suffered from some level of lactose mal-absorption. Despite this there is a huge push to encourage Chinese people to drink more milk. It is advertised as important for good health, the government funds milk-rounds to schools and the state-run television has aired programmes on the benefits of milk drinking. Many of the world's top dairy companies have entered China as a result of seeing the huge potential market of 1.3 billion inhabitants - though many of these companies find it hard to find reliable and hygienic supplies of raw milk in China itself.
Management has targeted expanding into Western Europe before the end of this year with expectations that its product will be well received. CEO Hamutal Yitzhak said at the Q2 earnings call:
The population in Western Europe is roughly 300 million, similar to the size of the U.S. However, research and polling has shown that Europeans are even more conscious of healthy eating habits.
In addition to supporting its products in the U.S. with preclinical and clinical studies, Else has had social media marketing programs, ads in medical journals a dedicated team to work with pediatricians in providing product information and samples for their patients. Else will incrementally increase its marketing campaign in each of the new territories it is entering.
Sales channel and product expansion
Else began sales in the U.S. in September 2020 with sales only online through its own website and through Amazon. The company added distribution agreements with two of the largest distributors KeHe Distributors and UNFI (United Natural Foods) and now has sales at over 3000 brick-and-mortar stores in the U.S. Else has also added other online platforms such as Walmart.com and Kroger.com. Online sales at these sites will naturally translate to shelf space at same-store brick-and-mortar locations.
The company's sales channel expansion plan has been well crafted. First, establish sales through an online presence and attract other online retailers. Then establish successful sales through a small chain and attract bigger chain stores while building a brand by offering a portfolio of products. The company initially began selling just one product for toddlers in 2020, added a kids powder mix in 2021, and subsequently added Toddler Omega and Super Cereal. Else plans to expand to offer 10 products with 20 SKUs this year. by the end of the year.
Key developments to watch
I expected the introduction of Else's Super Cereal, the world's first cereal to be certified free of toxins and heavy metals. Else management believes that the public, in general, has a perception that cereal is unhealthy and isn't aware that now there is a healthy choice. It is true that cereal sales have been declining. The company is planning to promote the cereal through samples at pediatric centers and retail outlets and through an advertising campaign.
More than half of American infants participate in the Women with Infant Children ("WIC") program. The program is funded by the federal government but administered by each individual state. Else has been working to gain WIC eligibility for its products. I learned from a recent conversation with Else management that the company is close to finalizing eligibility approval in a few states. WIC informs food retailers within its state once eligibility is granted. Since Else offers one-of-a-kind products, retailers in these states who aren't already on Else's distribution list will be eager to add Else products to their shelves. Else will probably pursue qualifying for the milk subsidy programs in China.
The company has begun working with medical distributors and food distributors to penetrate the hospital and educational outlets. Else is a natural for kindergarten through high school students who are lactose intolerant or obese and serve as a healthier alternative to milk or juice.
Revenue growth
Reported revenues for Q2 2022 were $2.3 million, 44% higher than for Q1 2022 and more than double the $0.9 million reported for Q2 2021. Sales through Amazon have topped $1 million with Q2 2022 reported revenue 84% higher than the previous quarter.
Sales for this year could reach $10 million by my estimate growing from 0 just two years ago. I estimate that with the territorial and new product expansion, next year's sales should be in the $25 million range. Then it gets really interesting. FDA approval for Else's infant formula is expected in early 2024 (as discussed below). This would be the first non-soy, non-dairy, plant-based food with a nutritional value equivalent to mother's mile. Lots of things could stall the timeline or worst case scenario is that FDA approval isn't granted, so I will leave 2024 and later revenue estimates for a later date.
Share info and valuation
There are 113 million shares outstanding with insiders owning about 27%. The company last reported $22 million in cash and no debt. The market cap is $63 million and the EV is $41 million. The company has sufficient funds to maintain operations for the next 12 months. The shares are trading at 4X my forward revenue estimate, which is expensive on the surface, but early commercial stage, high-growth stocks are always difficult to justify under traditional valuation metrics.
I prefer to use P/S for companies that aren't yet profitable and look out two or three years forward. Else has the potential to grow to $100 million in revenue in 2024 and billions going forward if it can bring the only non-soy, non-dairy, plant-based, nutritional equivalent to mother's mile food to market.
Pre-clinical, clinical and FDA
Else is providing medical proof to support its products are effective in improving gastric symptoms, support weight gain in infants and have nutritional value to promote healthy growth. The company completed its first preclinical study late in 2021 which demonstrated that Else infant formula demonstrated growth at least equivalent to dairy-based infant formula. A second preclinical study demonstrated the quality of the infant formula protein. Both of these preclinical trials are being used as first steps to meet the FDA requirements for Else's infant formula.
Else has begun the next steps in the FDA requirement with its first clinical study to demonstrate the tolerance of its products and shortly will begin its second clinical trial to demonstrate healthy growth in the healthy toddler population.
The company expects to conclude FDA trials in 2023 with an FDA decision expected in early 2024.
Risks
The company has enjoyed early success in introducing its product but has yet to establish that the success is not just an early fad. The company is entering new territories where it will need to develop a new customer appetite for its products.
Else has been funding its growth by issuing shares. The company will likely need to do a capital raise within a year which will be dilutive to shareholders. It's important to keep an eye on this dilution as there is a risk that the continuation of this strategy will place the company in a position where profitability will not become possible. At this point, as the company has established sales, it is important for investors to monitor going forward that revenue is growing at a faster pace than share count dilution.
Conclusion
In two years Else has grown revenues to what I expect will be about $10 million for this year with growth to accelerate as the company expands into a global presence and adds additional products. FDA approval for its anticipated flagship product is less than two years away. The company is providing game-changing products in the U.S. right now and is about to expand globally while it establishes its brand with a portfolio of product offerings. Else has the potential to be a billion-dollar revenue company in the not-too-distant future and commands a lofty valuation for investors seeking to get in early.
I wonder ... Did our new CEO canned our cannabis projects without mentionning it or has started a new business altogether ???
Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board
08/23/2022 9:00:00 AM
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce the appointment of Super Bowl XXVI MVP and mental health advocate Mr. Mark Rypien to its advisory board.
CEO Phil Floucault notes, “Mr. Rypien had a distinguished 13-year career in the NFL during which he was named to the All Madden Team in 1992, twice named to the Pro Bowl (1988 and 1991) and the first and only Canadian born Super Bowl MVP. As is widely reported and, as a result of sustained trauma during that time, Mark has suffered and continues to deal with some long-term effects. It is his advocacy for other athletes, military and civilians that brought us together. We see a synergy of working together to provide access to mental health support and to improve the mental health of all people. Whether it be our military and civilians or our athletes both professional and amateur.”
Praesidio Health (https://www.praesidiohealth.com/) is a Canadian medical research company that develops and validates natural health products using an evidence-based process. Included in the first round of formulations submitted to Health Canada for review and approval is a product dubbed “Quiet Peace.” “The trauma that I sustained from my career definitely effected my mental health,” says Mark. “Back then, there were no concussion protocols. You just shook it off and kept playing. I have carried those tackles with me long after I retired. During a particularly low point in my mental wellbeing, I attempted suicide. That was a wake-up call for me. I had had enough of feeling this way. It was time to start talking about mental health.”
Since then, Mark has become an advocate for athletic mental health and the mental health of our military and civilians.
“I’m excited to work with the Praesidio team to bring awareness to mental health and the potential that Praesidio products bring as part of a treatment regimen. The issues that I have dealt with and am continuing to deal with are faced by many professional athletes, military, and civilians alike. I am looking forward to helping support them,” says Mark.
On Behalf of The Board of Directors
My concern is that our CEO seems to put all its eggs in the same basket. Our current product line could generate a lot more revenues and even profits and waiting for FDA to maybe inform mothers is ridiculous. The FDA approval may take a lot of time, even assuming everything goes as expected ???
All our specialist does is repeat the same sories (dilution, debt, irrelevant historical data, ...). Whenever one of his prediction is proven wrong (as for dilution) he start with another tactic (debt).
This being said, It would be nice if Leon was somewhat more transparent regarding his view of our future.
Not only am I right but you confirm what I say by writing: 'help with investor relations and digital marketing.'
All our CEO cares about is to play big % numbers applied to small sales figure, addressing shareholders, trying to convince them that everything is great and put products on line or on shelves WITHOUT ANY EFFORT TO TALK TO THE MOTHERS ABOUT THE VALUE OF OUR OFFERINGSAND FOR THEIR BABIES.
For many quarters now, sales are much less than it should be, institutional investors stay away from our stock and our CEO stubbornly keep doing the same error entertaining small shareholdersand getting funds thru dilution instead of revenues.
She badly needs APPROPRIATE HELP but refuses to see it or worst doesn't know what approriate help is for her. For her, scientific subject is interesting and Marketing is a useless expense.
In 2023 the Company plans to continue research activity demonstrating the safety and tolerability of the infant formula as well as provide scientific support for Else products including preparation for additional clinical studies.“
Research, scientific support, clinical studies ... How about MARKETING so mothers find out that we exist and have a great offering for their babies NOW.
All our CEO cares about is scientific topics and she seems happy with minimum sales in a huge market,
The message the institutional investors and market tell her (us) is that (unless you are serious about growing the company, we will wait and see'.
I cannot imagine this company to go broke but I believe that fo awhile our CEO will keep diluting us and wonder if she will ever understand how stupid her approach to the market is. Had she been using a small part of the cash on books to talk to mothers about our products and about the features of the current offerings we have, revenues could easily be 3 time what they currently are.
Our CEO however only entertain scientists (doctors) and talk to shareholders not understanding that SELLING (not only sending boxes to put on shelves) is one critical part of the desired results.
MAYBE one of these days someone will get to her and make her realise that she dreams of future instead of aiming at generating revenue RIGHT NOW.
Whatever the company does relative to formula, the fact is tha we have plenty of products on plenty of shelves and stupidly expect mothers to figure out what these boxes on shelves are all about.
What do we do to promote sales, we talk to doctors and shareholders.
Any serious advertizing effort (we can afford it) AIM AT MOTHERS in the markets would rapidly increase our sales (revenues) ... unless we cannot answer demand ???
Institutional investors do not invest because they understand that our management is betting on formula and FDA's approval is still more or less far down the road.
Business management is very absent in our company but it is obvious our management doesn't have the skill required to grow our business based on current products. If they have FDA's approval and keep not telling the market aimed at,, they will keep
Nice but here again, she promotes herself in medias offering free coverage of our products instead of ADVERTIZING thru medias addressing her targetted consumers (baby mothers). For a mother to learn about us, she must have a doctor voluntarely promoting our products (???) mothers reading business magazines or shareholders. All of them taken together probably makes 5% (generously) of our targetted market.
This woman may be great in her domaine(s) but she obviously doesn't have any clue of what Marketing/Advertizing is all about. Considering the market we aim at, the current shortage of baby food products and the specifics of our offerings, sales of more or less $8M/year, after 2 years in the market is disastrous. The woman does brag about our % of growth not understanding that it's a percentage applied to very small numbers.
Financials are currently quite ugly but I honestly believe that our management is on the right track with their new strategy.
By the end of 2020 I made great with this stock and soldout early 2021 when I saw the downward trend happening. I however kept this stock on the radar (feeling great about my decision)
Last May, considering the drastic turn the management did, I bought back shares (().29) thinking that management did what had to be done.
I am not surprised by the recent financials and am confident that the company's future is as great as it ever was. However time is of the essence and my current pla is to wait for Q1 FY2023 results to see how great or not my decision will have been.